DeciBio Ventures flags pharma services sector push into AI-enabled clinical development in Q3 2026 roundup

By Public Technologies
  • DeciBio Ventures’ Q3 2026 pharma services round-up flagged accelerating AI adoption across clinical development platforms.
  • ICON entered a multi-year collaboration with Anthropic to embed Claude into Orbis for trial operations, including site selection.
  • Samsung Biologics launched an all-cash tender offer of $1.8 billion for PolyPeptide, targeting peptide capacity tied to GLP-1 demand.
  • Tempus AI agreed to acquire Personalis to add MRD testing, tightening integration across its precision oncology platform.
  • Fortrea agreed to buy Worldwide’s early phase services unit for $45 million, expanding early-stage capabilities via lab and clinic assets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DeciBio Ventures published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.